Eli Lilly will assess the company’s JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Incyte’s ruxolitinib cream hit the drug’s primary endpoint in the Phase III TRuE-AD2 trial of atopic dermatitis in adolescents and adults. Incyte and Eli Lilly announced topline results from the Phase III trial (FREEZE-AD4) of baricitinib in topical corticosteroids for the treatment of adults with moderate to severe atopic dermatitis who did not respond to treatment with cyclosporine.
The U.S. Food and Drug Administration approved Pfizer Inc.’s Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers.
AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
The U.S. Food and Drug Administration approved Incyte Corp.’s Jakafi as the first treatment for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
Pfizer Inc.’s experimental atopic dermatitis treatment abrocitinib met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease.
Sierra Oncology Inc. announced that the clinical-stage drug-development company acquired the drug candidate momelotinib from Gilead Sciences.
Pfizer Inc. announced that the European Commission approved Xeljanz (tofacitinib citrate) 10 mg twice daily for at least eight weeks, followed by Xeljanz 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.
